Vanda Pharmaceuticals (NASDAQ:VNDA) Raised to Strong-Buy at Zacks Research

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

VNDA has been the subject of a number of other research reports. HC Wainwright upped their price objective on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Finally, Jefferies Financial Group raised their target price on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Vanda Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $13.63.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock opened at $6.12 on Wednesday. The stock’s 50-day moving average price is $7.34 and its 200 day moving average price is $5.67. The company has a quick ratio of 3.10, a current ratio of 3.12 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $361.69 million, a PE ratio of -1.64 and a beta of 0.62. Vanda Pharmaceuticals has a 52-week low of $3.81 and a 52-week high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The company had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 21.88%. As a group, equities research analysts forecast that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Torren Management LLC acquired a new stake in Vanda Pharmaceuticals in the fourth quarter valued at $25,000. Russell Investments Group Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 5,328 shares during the last quarter. CWM LLC raised its holdings in shares of Vanda Pharmaceuticals by 424.6% in the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 7,575 shares during the last quarter. Quarry LP purchased a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at $53,000. Finally, Cerity Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at $69,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Fanapt momentum: Full‑year 2025 Fanapt net sales rose 24% to $117.3M, driven by higher prescriptions — supports durable product revenue growth. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: NEREUS approval and Bysanti PDUFA: NEREUS (tradipitant) approved for prevention of motion‑induced vomiting; Bysanti (milsaperidone) NDA under FDA review with PDUFA target Feb 21, 2026 — a potential upside catalyst if approved. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst coverage mixed but constructive: recent buy/overweight ratings and price targets remain above the current share price (median target ~$12.50), indicating upside in some broker forecasts. Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Earnings miss and widening net loss: Q4 revenue (~$56–57M) missed estimates and diluted EPS was -2.39, substantially below forecasts; the company reported a large net loss and gross loss for the quarter. Vanda Pharmaceuticals Inc (VNDA) Q4 2025 Earnings Call Highlights
• Negative Sentiment: Below‑consensus FY2026 revenue guidance: company guided to $230M–$260M vs. consensus ~$273M — guidance shortfall weighs on near‑term expectations. (Guidance noted in company release and market reports.)
• Negative Sentiment: Cash burn and balance sheet pressure: operating cash outflow increased, cash and equivalents fell to roughly $70M, and liabilities rose — increases focus on runway and financing risk. Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Investor litigation announced: Pomerantz LLP is investigating claims on behalf of Vanda investors — adds legal risk and near‑term uncertainty. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.